Novela el tratamiento del ictus Pases de Seguridad de escena de la UCI-Led de ensayos clínicos
A clinical research study of a new treatment to restore damaged brain cells from stroke has passed a safety milestone, according to the neurologist at UC Irvine, who led the effort.
Dr. Steven C. Cramer said the patients showed no adverse effects after sequential administration of growth factors, stimulating the creation of neurons in stroke-damaged brain areas. All new security pharmaceutical treatments should pass this stage before doctors could study their effectiveness in future studies.
The results of a Phase IIa trial appear on the website of the journal Stroke, a journal of the American Association Heart.
Within two days of suffering an ischemic stroke, patients were placed in a nine-day course of treatment, starting with three injections once daily of beta-hCG, a hormone that causes the growth of stem cells neural . Then, once received three daily injections of erythropoietin, a hormone that directs neural stem cells to become neurons.
Cramer, associate professor of neurology at UCI, said this combination of growth factors has been demonstrated in animal studies to generate the creation of the neuron leading to the recovery range of motion.
The study of human security, teamed with doctors at the University of California Irvine Medical Center, Hoag Memorial Hospital Presbyterian in Newport Beach, California, and the University of Calgary in Canada. Treatment was administered to 15 patients. There were no security problems, and most patients with minimal or no disability after three months.
A Phase IIb trial currently underway to compare the movement therapy with placebo.
The study is supported by Stem Cell Therapeutics - a Canadian biotechnology company that devised an approach using the sequence specific growth factors - and the National Center for Research Resources. Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
0 comments:
Post a Comment